miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252. doi:10.1097/pas.000000000000053026492179
   PubMed Web of Science ®Google Scholar
• Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol. 2016;69(3):428–435. doi:10.1016/j.eururo.2015.06.04626166626
   PubMed Web of Science ®Google Scholar
• Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019–1024. doi:10.1016/j.eururo.2012.01.05022336380
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/s0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27(45):5959–5974. doi:10.1038/onc.2008.27418836476
   PubMed Web of Science ®Google Scholar
• Lichner Z, Ding Q, Samaan S, et al. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. J Pathol. 2015;237(2):226–237. doi:10.1002/path.456826011734
   PubMed Web of Science ®Google Scholar
• Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33(2):135–147. doi:10.1038/onc.2013.5423455326
   PubMed Web of Science ®Google Scholar
• Aghdam SG, Ebrazeh M, Hemmatzadeh M, et al. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234(7):9927–9942. doi:10.1002/jcp.2794830536403
   PubMed Web of Science ®Google Scholar
• Rizzo M. Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188481. doi:10.1016/j.bbcan.2020.18848133217485
   PubMed Web of Science ®Google Scholar
• Saxby H, Mikropoulos C, Boussios S. An update on the prognostic and predictive serum biomarkers in metastatic prostate cancer. Diagnostics. 2020;10(8). doi:10.3390/diagnostics10080549
   Web of Science ®Google Scholar
• Ghafouri-Fard S, Shoorei H, Taheri M. Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer. Gene. 2020;759:144995. doi:10.1016/j.gene.2020.14499532721477
   PubMed Web of Science ®Google Scholar
• Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of MicroRNAs as prostate cancer biomarkers. Eur Urol. 2016;70(2):312–322. doi:10.1016/j.eururo.2015.12.05426806656
   PubMed Web of Science ®Google Scholar
• Martínez-González LJ, Sánchez-Conde V, González-Cabezuelo JM, et al. Identification of MicroRNAs as viable aggressiveness biomarkers for prostate cancer. Biomedicines. 2021;9(6):646. doi:10.3390/biomedicines906064634198846
   PubMed Web of Science ®Google Scholar
• Valera VA, Parra-Medina R, Walter BA, Pinto P, Merino MJ. microRNA expression profiling in young prostate cancer patients. J Cancer. 2020;11(14):4106–4114. doi:10.7150/jca.3784232368293
   PubMed Web of Science ®Google Scholar
• Gao S, Zhao Z, Wu R, Wu L, Tian X, Zhang Z. MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met. Biomed Pharmacother. 2019;109:1406–1410. doi:10.1016/j.biopha.2018.10.09830551391
   PubMed Web of Science ®Google Scholar
• Hudson RS, Yi M, Esposito D, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2012;40(8):3689–3703. doi:10.1093/nar/gkr122222210864
   PubMed Web of Science ®Google Scholar
• Li T, Li RS, Li YH, et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol. 2012;187(4):1466–1472. doi:10.1016/j.juro.2011.11.08222341810
   PubMed Web of Science ®Google Scholar
• Kurul NO, Ates F, Yilmaz I, Narli G, Yesildal C, Senkul T. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease. Prostate. 2019;79(10):1125–1132. doi:10.1002/pros.2382531045265
   PubMed Web of Science ®Google Scholar
• Mishra S, Deng JJ, Gowda PS, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2014;33(31):4097–4106. doi:10.1038/onc.2013.37424037531
   PubMed Web of Science ®Google Scholar
• Lin ZY, Chen G, Zhang YQ, et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16(1):48. doi:10.1186/s12943-017-0615-x28241827
   PubMed Web of Science ®Google Scholar
• Su SF, Chang YW, Andreu-Vieyra C, et al. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 2013;32(39):4694–4701. doi:10.1038/onc.2012.48323085757
   PubMed Web of Science ®Google Scholar
• Leite KR, Tomiyama A, Reis ST, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011;185(3):1118–1122. doi:10.1016/j.juro.2010.10.03521255804
   PubMed Web of Science ®Google Scholar
• McDonald AC, Vira M, Walter V, et al. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. Prostate. 2019;79(9):961–968. doi:10.1002/pros.2380330958910
   PubMed Web of Science ®Google Scholar
• Xu WX, Liu Z, Deng F, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11(11):6739–6753.31814885
   PubMed Web of Science ®Google Scholar
• Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013;108(12):2573–2581. doi:10.1038/bjc.2013.25023703249
   PubMed Web of Science ®Google Scholar
• Kristensen H, Haldrup C, Strand S, et al. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014;20(8):2169–2181. doi:10.1158/1078-0432.Ccr-13-264224737792
   PubMed Web of Science ®Google Scholar
• Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem. 2013;59(1):261–269. doi:10.1373/clinchem.2012.19150223136246
   PubMed Web of Science ®Google Scholar
• Lin ZY, Huang YQ, Zhang YQ, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 2014;135(3):541–550. doi:10.1002/ijc.2870724382668
   PubMed Web of Science ®Google Scholar
• Saini S, Majid S, Shahryari V, et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 2012;72(14):3618–3630. doi:10.1158/0008-5472.Can-12-054022552290
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-630944313
   PubMed Web of Science ®Google Scholar
• Ai C, Kong L. CGPS: a machine learning-based approach integrating multiple gene set analysis tools for better prioritization of biologically relevant pathways. J Genet Genomics. 2018;45(9):489–504. doi:10.1016/j.jgg.2018.08.00230292791
   PubMed Web of Science ®Google Scholar
• Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: an online resource for prediction of microRNA binding sites. PLoS One. 2018;13(10):e0206239. doi:10.1371/journal.pone.020623930335862
   PubMed Web of Science ®Google Scholar
• Berg KD, Thomsen FB, Nerstrøm C, et al. The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - A matched-pair analysis. BJU Int. 2016;117(6):883–889. doi:10.1111/bju.1343926823232
   PubMed Web of Science ®Google Scholar
• Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–760. doi:10.1111/j.1464-410X.2012.11611.x23464824
   PubMed Web of Science ®Google Scholar
• Kweldam CF, Wildhagen MF, Bangma CH, van Leenders GJ. Disease-specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy. BJU Int. 2015;116(2):230–235. doi:10.1111/bju.1287925060593
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–213. doi:10.1056/NEJMoa111316222808955
   PubMed Web of Science ®Google Scholar
• Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36(9):1346–1352. doi:10.1097/PAS.0b013e3182556dcd22531173
   PubMed Web of Science ®Google Scholar
• Bul M, van den Bergh RC, Zhu X, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110(11):1672–1677. doi:10.1111/j.1464-410X.2012.11434.x22928973
   PubMed Web of Science ®Google Scholar
• Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–875. doi:10.1016/j.juro.2010.10.05721239008
   PubMed Web of Science ®Google Scholar
• Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–277. doi:10.1200/jco.2014.55.119225512465
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Pastore AL, Lombardo R, et al. The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. Eur J Surg Oncol. 2018;44(6):835–839. doi:10.1016/j.ejso.2017.12.00329395435
   PubMed Web of Science ®Google Scholar
• Corcoran NM, Hong MK, Casey RG, et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011;108(8 Pt 2):E202–E210. doi:10.1111/j.1464-410X.2011.10119.x21443656
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology. 2007;69(3):495–499. doi:10.1016/j.urology.2006.10.03617382152
   PubMed Web of Science ®Google Scholar
• Blute ML, Shiau JM, Truong M, et al. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol. 2017;35(5):729–735. doi:10.1007/s00345-016-1933-027631325
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Karnes RJ, Crispen PL, et al. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009;181(1):95–104; discussion 104. doi:10.1016/j.juro.2008.09.016
   PubMed Web of Science ®Google Scholar
• Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014;114(6b):E18–e24. doi:10.1111/bju.1255424712895
   PubMed Web of Science ®Google Scholar
• Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185–2190. doi:10.1200/jco.2010.32.811221464416
   PubMed Web of Science ®Google Scholar
• Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol. 2008;179(3):901–4;discussion 904–5. doi:10.1016/j.juro.2007.10.062
   PubMed Web of Science ®Google Scholar
• Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. Cancer Res. 2013;73(16):5163–5168. doi:10.1158/0008-5472.Can-13-042723946472
   PubMed Web of Science ®Google Scholar
• Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin Ther Targets. 2021;25(5):329–333. doi:10.1080/14728222.2021.195122634225539
   PubMed Web of Science ®Google Scholar
• Trock BJ, Fedor H, Gurel B, et al. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Mod Pathol. 2016;29(7):764–771. doi:10.1038/modpathol.2016.6327080984
   PubMed Web of Science ®Google Scholar
• Lotan TL, Carvalho FL, Peskoe SB, et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2015;28(1):128–137. doi:10.1038/modpathol.2014.8524993522
   PubMed Web of Science ®Google Scholar
• Ioannidou E, Moschetta M, Shah S, et al. Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets. Int J Mol Sci. 2021;22(18):9926. doi:10.3390/ijms2218992634576107
   PubMed Web of Science ®Google Scholar
• Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Lett. 2014;342(2):248–256. doi:10.1016/j.canlet.2012.02.01122391123
   PubMed Web of Science ®Google Scholar
• Ottman R, Nguyen C, Lorch R, Chakrabarti R. MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer. 2014;13:1–21. doi:10.1186/1476-4598-13-124387052
   PubMed Web of Science ®Google Scholar
• Tsuchiyama K, Ito H, Taga M, et al. Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate. 2013;73(8):827–834. doi:10.1002/pros.2262623184537
   PubMed Web of Science ®Google Scholar
• Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011;32(5):772–778. doi:10.1093/carcin/bgr03621349819
   PubMed Web of Science ®Google Scholar
• Lin KH, Kumar VB, Shanmugam T, et al. miR-145-5p targets paxillin to attenuate angiotensin II-induced pathological cardiac hypertrophy via downregulation of Rac 1, pJNK, p-c-Jun, NFATc3, ANP and by Sirt-1 upregulation. Mol Cell Biochem. 2021;476(9):3253–3260. doi:10.1007/s11010-021-04100-w33886061
   PubMed Web of Science ®Google Scholar
• Kotelevets L, Chastre E. Rac1 signaling: from intestinal homeostasis to colorectal cancer metastasis. Cancers. 2020;12(3):665. doi:10.3390/cancers12030665
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang D, Zhao Y, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23(9):1055–1062. doi:10.1038/nm.437928805822
   PubMed Web of Science ®Google Scholar